Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron Pharmaceuticals has entered into an agreement with Sanofi-Aventis to use Regeneron's proprietary VelociGene technology platform to supply Sanofi-Aventis with genetically modified mammalian models of gene function and disease.
Subscribe to our email newsletter
Sanofi-Aventis will pay Regeneron a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by Sanofi-Aventis. Sanofi-Aventis will use these models for its internal research programs, outside the scope of its antibody collaboration with Regeneron.
Regeneron and Sanofi-Aventis have previously entered into a collaboration agreement for the discovery, development, and commercialization of human monoclonal antibodies based on Regeneron’s proprietary VelociSuite of technologies, including VelociGene, VelociMouse, VelocImmune, and VelociMab.
David Valenzuela, chief of VelociGene operations at Regeneron, said: “We have extensive experience using the VelociGene platform as part of our internal research activities, and it has proven to be extremely useful for identifying new gene targets for drug R&D.”